Connect Biopharma Holdings Stock Today
| CNTB Stock | USD 1.35 0.19 12.34% |
Performance4 of 100
| Odds Of DistressOver 55
|
Connect Biopharma is trading at 1.35 as of the 23rd of April 2024, a -12.34 percent decrease since the beginning of the trading day. The stock's open price was 1.54. Connect Biopharma has over 55 % chance of experiencing financial distress in the next 2 years of operation and did not have a very good performance during the last 90 trading days. Equity ratings for Connect Biopharma Holdings are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 23rd of February 2024 and ending today, the 23rd of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 19th of March 2021 | Category Healthcare | Classification Health Care |
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company was founded in 2012 and is headquartered in Taicang, China. The company has 55.1 M outstanding shares of which 115.47 K shares are currently shorted by private and institutional investors with about 1.11 trading days to cover. More on Connect Biopharma Holdings
Moving together with Connect Stock
| 0.72 | OPT | Opthea | PairCorr |
Moving against Connect Stock
| 0.66 | GNTA | Genenta Science SpA Report 24th of April 2024 | PairCorr |
| 0.58 | ANAB | AnaptysBio Financial Report 9th of May 2024 | PairCorr |
| 0.56 | MGTX | MeiraGTx Holdings PLC Financial Report 9th of May 2024 | PairCorr |
| 0.55 | JNJ | Johnson Johnson Aggressive Push | PairCorr |
| 0.54 | PCRX | Pacira Pharmaceuticals Financial Report 1st of May 2024 | PairCorr |
| 0.5 | PCVX | VaxcyteInc Financial Report 13th of May 2024 | PairCorr |
| 0.49 | ALKS | Alkermes Plc Financial Report 24th of April 2024 | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Connect Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Connect Biopharma's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Connect Biopharma or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| President CoFounder | Wubin MBA | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Connect Biopharma report their recommendations after researching Connect Biopharma's financial statements, talking to executives and customers, or listening in on Connect Biopharma's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Connect Biopharma. The Connect consensus assessment is calculated by taking the average forecast from all of the analysts covering Connect Biopharma. | ||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key measurements obtained from Connect Biopharma's financial statements, Connect Biopharma Holdings is not in a good financial situation at this time. It has a very high odds of going through financial crisis in May. Financial strength of Connect Biopharma is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||
Connect Biopharma's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Connect Biopharma's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Connect Biopharma's financial leverage. It provides some insight into what part of Connect Biopharma's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Connect Biopharma Holdings (CNTB) is traded on NASDAQ Exchange in USA. It is located in 12265 El Camino Real, San Diego, CA, United States, 92130 and employs 81 people. Connect Biopharma is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 74.39 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Connect Biopharma's market, we take the total number of its shares issued and multiply it by Connect Biopharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Connect Biopharma conducts business under Biotechnology sector and is part of Health Care industry. The entity has 55.1 M outstanding shares of which 115.47 K shares are currently shorted by private and institutional investors with about 1.11 trading days to cover.
Connect Biopharma Holdings currently holds about 1.28 B in cash with (47.93 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 23.26, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Connect Biopharma Probability Of Bankruptcy
Ownership AllocationConnect Biopharma holds a total of 55.1 Million outstanding shares. Connect Biopharma Holdings retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Connect Ownership Details
Connect Stock Price Odds Analysis
What are Connect Biopharma's target price odds to finish over the current price? Depending on a normal probability distribution, the odds of Connect Biopharma jumping above the current price in 90 days from now is about 52.66%. The Connect Biopharma Holdings probability density function shows the probability of Connect Biopharma stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.0492 suggesting Connect Biopharma Holdings market returns are sensitive to returns on the market. As the market goes up or down, Connect Biopharma is expected to follow. Additionally, connect Biopharma Holdings has an alpha of 0.6464, implying that it can generate a 0.65 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
Based on a normal probability distribution, the odds of Connect Biopharma to move above the current price in 90 days from now is about 52.66 (This Connect Biopharma Holdings probability density function shows the probability of Connect Stock to fall within a particular range of prices over 90 days) .
Connect Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Connect Biopharma that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Connect Biopharma's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Connect Biopharma's value.| Instituion | Recorded On | Shares | |
| Royal Bank Of Canada | 2023-12-31 | 449 | |
| Jpmorgan Chase & Co | 2023-12-31 | 121 | |
| Qube Research & Technologies | 2023-12-31 | 46.0 | |
| Fmr Inc | 2023-12-31 | 23.0 | |
| Susquehanna International Group, Llp | 2023-09-30 | 0.0 | |
| Ikarian Capital, Llc | 2023-09-30 | 0.0 | |
| Morgan Stanley - Brokerage Accounts | 2023-12-31 | 0.0 | |
| Kynam Capital Management, Lp | 2023-12-31 | 0.0 | |
| Adage Capital Partners Gp Llc | 2023-12-31 | 0.0 | |
| Ra Capital Management, Llc | 2023-12-31 | 3.1 M | |
| Bml Capital Management Llc | 2023-12-31 | 2.1 M |
Connect Biopharma Historical Income Statement
Connect Biopharma Holdings Income Statement is one of the three primary financial statements used for reporting Connect's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Connect Biopharma revenue and expense. Connect Biopharma Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At present, Connect Biopharma's Other Operating Expenses is projected to increase significantly based on the last few years of reporting. The current year's Net Interest Income is expected to grow to about 2.8 M, whereas Interest Expense is forecasted to decline to about 21.9 K. View More FundamentalsConnect Stock Against Markets
Picking the right benchmark for Connect Biopharma stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Connect Biopharma stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Connect Biopharma is critical whether you are bullish or bearish towards Connect Biopharma Holdings at a given time. Please also check how Connect Biopharma's historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Connect Biopharma without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Latest Portfolios Now
Latest PortfoliosQuick portfolio dashboard that showcases your latest portfolios |
| All Next | Launch Module |
Connect Biopharma Corporate Management
Elected by the shareholders, the Connect Biopharma's board of directors comprises two types of representatives: Connect Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Connect. The board's role is to monitor Connect Biopharma's management team and ensure that shareholders' interests are well served. Connect Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Connect Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Steven Chan | Chief Officer | Profile | |
| Raul Collazo | VP Affairs | Profile | |
| Zheng Wei | CEO CoFounder | Profile | |
| Lei Sun | VP CMC | Profile | |
| Jiang JD | General Officer | Profile | |
| Malinda Longphre | Head Operations | Profile |
How to buy Connect Stock?
Before investing in Connect Biopharma, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Connect Biopharma. To buy Connect Biopharma stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Connect Biopharma. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Connect Biopharma stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Connect Biopharma Holdings stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Connect Biopharma Holdings stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Connect Biopharma Holdings, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Connect Stock please use our How to Invest in Connect Biopharma guide.
Already Invested in Connect Biopharma Holdings?
The danger of trading Connect Biopharma Holdings is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Connect Biopharma is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Connect Biopharma. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Connect Biopharma is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Connect Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Connect Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Connect Biopharma Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Connect Biopharma Holdings Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Connect Biopharma Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the AI Investment Finder module to use AI to screen and filter profitable investment opportunities.
Complementary Tools for Connect Stock analysis
When running Connect Biopharma's price analysis, check to measure Connect Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Connect Biopharma is operating at the current time. Most of Connect Biopharma's value examination focuses on studying past and present price action to predict the probability of Connect Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Connect Biopharma's price. Additionally, you may evaluate how the addition of Connect Biopharma to your portfolios can decrease your overall portfolio volatility.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |
Is Connect Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Connect Biopharma. If investors know Connect will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Connect Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.08) | Return On Assets (0.27) | Return On Equity (0.46) |
The market value of Connect Biopharma is measured differently than its book value, which is the value of Connect that is recorded on the company's balance sheet. Investors also form their own opinion of Connect Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Connect Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Connect Biopharma's market value can be influenced by many factors that don't directly affect Connect Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Connect Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Connect Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Connect Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.